Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
06.03. | Tris to ask for approval of dual-acting pain drug | ||
05.03. | Jazz expands in oncology with $935M deal for Chimerix | ||
05.03. | Bayer braces for 'difficult' year before turnaround pays dividends | ||
04.03. | Sofinnova secures €1.2B for new biotech investments | ||
04.03. | Neumora bids farewell to R&D head; Biohaven's 'one step forward, one step back' data | ||
04.03. | Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda | ||
03.03. | Biotech startup pulls in $187M to make 'multi-payload' ADCs | ||
03.03. | AbbVie gets into obesity with $350M deal for once-weekly shot | ||
03.03. | Protagonist says Takeda-partnered drug succeeds in rare blood cancer | ||
28.02. | Leqembi, after delay, gets back on track toward EU approval | ||
28.02. | BridgeBio oncology spinout to go public in blank-check merger | ||
28.02. | Praxis hits trial setback; Bristol Myers lays off staff in New Jersey | ||
27.02. | FDA meeting on flu vaccine composition is canceled | ||
27.02. | Vertex ends gene editing research pact with Verve | ||
26.02. | Lilly CEO wields manufacturing plans to push pharma-friendly policies | ||
26.02. | AstraZeneca's next breast cancer drug; Madrigal's accelerating MASH launch | ||
26.02. | Lilly expands US manufacturing build-out with $50B target | ||
26.02. | Eikon raises $351M in one of the year's largest biotech venture rounds | ||
25.02. | Drug compounders sue FDA over declaration ending Wegovy shortage | ||
25.02. | Regeneron gene therapy helps deaf children hear in small study | ||
25.02. | 'Fear and uncertainty': Biotech investors warn of impact from NIH research cuts | ||
25.02. | FDA brings back some fired device office staff | ||
24.02. | Mirum drug for rare genetic disease gains FDA approval | ||
24.02. | Summit partners with Pfizer to study bispecific, ADC combinations | ||
24.02. | Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer |